Nfec stocktwits
Neovasc's stock nearly triples after submission of PMA for angina treatment Shares of Neovasc Inc. nearly tripled in active premarket trading Tuesday, after the medical device company said it submitted a premarket approval application (PMA) for its Neovasc Reducer, for the treatment of refactory angina. This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which …